Tag: endpoint harmonization

Choosing Primary vs. Composite Endpoints in Orphan Drug Studies

Posted on digi By digi

Choosing Primary vs. Composite Endpoints in Orphan Drug Studies How to Choose Between Primary and Composite Endpoints in Rare Disease Trials Introduction: The Challenge of Endpoint Selection in Rare Diseases In rare disease clinical trials, defining suitable endpoints is one of the most critical and complex tasks. With small populations, heterogeneous symptoms, and limited natural…

Read More “Choosing Primary vs. Composite Endpoints in Orphan Drug Studies” »

Rare and Orphan Disease Trials, Trial Design & Methodology

Implementing Basket Trials in Rare Genetic Disorders

Posted on digi By digi

Implementing Basket Trials in Rare Genetic Disorders How Basket Trials Are Revolutionizing Rare Genetic Disorder Studies Introduction: Why Basket Trials Fit Rare Disease Research In the realm of rare and ultra-rare genetic diseases, traditional clinical trial structures often fall short due to limited patient populations and disease heterogeneity. Basket trials provide an innovative solution by…

Read More “Implementing Basket Trials in Rare Genetic Disorders” »

Rare and Orphan Disease Trials, Trial Design & Methodology

How Novel Endpoints Led to Rare Disease Drug Approval

Posted on digi By digi

How Novel Endpoints Led to Rare Disease Drug Approval Innovative Clinical Endpoints Driving Rare Disease Drug Approvals Introduction: The Importance of Novel Endpoints in Rare Disease Trials Rare disease clinical trials face the unique challenge of enrolling very small patient populations, often fewer than a few hundred globally. Traditional endpoints such as overall survival, large-scale…

Read More “How Novel Endpoints Led to Rare Disease Drug Approval” »

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Multi-Center Trials for Global Vaccine Evaluation

Posted on digi By digi

Multi-Center Trials for Global Vaccine Evaluation Designing Global Multi-Center Vaccine Trials That Hold Up Everywhere Why Go Multi-Center and Global: Scientific, Statistical, and Regulatory Drivers Vaccine programs turn to multi-center, multi-country designs when they need speed, statistical power, and generalizability. Incidence varies across geographies and seasons; running across regions shortens accrual to reach event targets…

Read More “Multi-Center Trials for Global Vaccine Evaluation” »

Phase I–IV Vaccine Trials, Vaccine Clinical Trials